Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C.

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions. Particularly, interferon (IFN) has been known to induce or exacerbate autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) in hepatitis C virus patients. We describe a severe, acute-onset antimitochondrial antibody (AMA)-M2 positive AIH appearing during the last weeks of SoC in a woman with chronic hepatitis C and no previous history of autoimmunity, and resolving on protracted steroids. In this context, the relevance of the characterization of the immunoglobulin isotype of portal plasma cells for a more appropriate diagnosis of autoimmune liver diseases can be emphasized.
Lingua originaleEnglish
pagine (da-a)428-432
Numero di pagine5
RivistaHepatology Research
Volume42
Stato di pubblicazionePublished - 2012

Fingerprint

Autoimmune Hepatitis
Chronic Hepatitis C
Standard of Care
Interferons
Biliary Liver Cirrhosis
Antibodies
Immunoglobulin Isotypes
Ribavirin
Plasma Cells
Autoimmunity
Hepacivirus
Autoimmune Diseases
Liver Diseases
Steroids

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cita questo

@article{3d6a8a35206c46ff8a19d2a4c06b059c,
title = "Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C.",
abstract = "The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions. Particularly, interferon (IFN) has been known to induce or exacerbate autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) in hepatitis C virus patients. We describe a severe, acute-onset antimitochondrial antibody (AMA)-M2 positive AIH appearing during the last weeks of SoC in a woman with chronic hepatitis C and no previous history of autoimmunity, and resolving on protracted steroids. In this context, the relevance of the characterization of the immunoglobulin isotype of portal plasma cells for a more appropriate diagnosis of autoimmune liver diseases can be emphasized.",
keywords = "Antimitochondrial antibodies, autoimmune hepatitis, chronic hepatitis C",
author = "Daniela Cabibi and Macaluso, {Fabio Salvatore} and Nicola Alessi",
year = "2012",
language = "English",
volume = "42",
pages = "428--432",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C.

AU - Cabibi, Daniela

AU - Macaluso, Fabio Salvatore

AU - Alessi, Nicola

PY - 2012

Y1 - 2012

N2 - The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions. Particularly, interferon (IFN) has been known to induce or exacerbate autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) in hepatitis C virus patients. We describe a severe, acute-onset antimitochondrial antibody (AMA)-M2 positive AIH appearing during the last weeks of SoC in a woman with chronic hepatitis C and no previous history of autoimmunity, and resolving on protracted steroids. In this context, the relevance of the characterization of the immunoglobulin isotype of portal plasma cells for a more appropriate diagnosis of autoimmune liver diseases can be emphasized.

AB - The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions. Particularly, interferon (IFN) has been known to induce or exacerbate autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) in hepatitis C virus patients. We describe a severe, acute-onset antimitochondrial antibody (AMA)-M2 positive AIH appearing during the last weeks of SoC in a woman with chronic hepatitis C and no previous history of autoimmunity, and resolving on protracted steroids. In this context, the relevance of the characterization of the immunoglobulin isotype of portal plasma cells for a more appropriate diagnosis of autoimmune liver diseases can be emphasized.

KW - Antimitochondrial antibodies, autoimmune hepatitis, chronic hepatitis C

UR - http://hdl.handle.net/10447/97447

M3 - Article

VL - 42

SP - 428

EP - 432

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

ER -